Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells
Barry, S. M., Zisoulis, D. G., Neal, J. W., Clipstone, N. A., & Kansas, G. S. (2003). Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells. BLOOD, 102(5), 1771–1778.

Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.
Neal, J. W., & Sequist, L. V. (2010). Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. Nature Reviews. Clinical Oncology, 7(2), 71–72.

Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh
Neal, J. W., & Sequist, L. V. (2010). Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 11(1-2), 36–44.

AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer
Neal, J., & Wakelee, H. (2010). AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 12(4), 487–95.

The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
Neal, J. W. (2010). The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. FUTURE ONCOLOGY, 6(12), 1827–1832.

One Allele's Loss Is Another's Gain: Alterations of NKX2-8 in Non-Small Cell Lung Cancer
Neal, J. W., & Shaw, A. T. (2011). One Allele's Loss Is Another's Gain: Alterations of NKX2-8 in Non-Small Cell Lung Cancer. CLINICAL CANCER RESEARCH, 17(4), 638–639.

Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer
Riess, J. W., & Neal, J. W. (2011). Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 6(11), S1797–S1798.

Current Management of Small Cell Lung Cancer
Neal, J. W., Gubens, M. A., & Wakelee, H. A. (2011). Current Management of Small Cell Lung Cancer. CLINICS IN CHEST MEDICINE, 32(4), 853-?

Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer
Neal, J. W., & Sequist, L. V. (2012). Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(18), 2280–2282.

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., … Reck, M. (2012). Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study. JOURNAL OF CLINICAL ONCOLOGY, 30(17), 2046–2054.

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
Diaz-Padilla, I., Siu, L. L., San Pedro-Salcedo, M., Razak, A. R. A., Colevas, A. D., Shepherd, F. A., … Wakelee, H. A. (2012). A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. BRITISH JOURNAL OF CANCER, 107(4), 604–11.

A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer
Goldberg, S. B., Supko, J. G., Neal, J. W., Muzikansky, A., Digumarthy, S., Fidias, P., … Sequist, L. V. (2012). A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 7(10), 1602–1608.

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.
Nguyen, K.-S. H., & Neal, J. W. (2012). First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics : Targets & Therapy, 6, 337–45.

Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.
Riess, J. W., & Neal, J. W. (2012). Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer. Journal of Thoracic Oncology , 7(16), S385–6.

Aflibercept in lung cancer
Neal, J. W., & Wakelee, H. A. (2013). Aflibercept in lung cancer. EXPERT OPINION ON BIOLOGICAL THERAPY, 13(1), 115–20.

A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. Journal of Thoracic Oncology , 8(2), e17–8.

A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib
Riess, J. W., Nagpal, S., Neal, J. W., & Wake, H. A. (2013). A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(4), 389–94.

REGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE-ACTIVATED ATP-DEPENDENT PHOSPHORYLATION OF HPR IN LACTOBACILLUS-BREVIS
Ye, J. J., Neal, J. W., Cui, X. W., Reizer, J., & Saier, M. H. (1994). REGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE-ACTIVATED ATP-DEPENDENT PHOSPHORYLATION OF HPR IN LACTOBACILLUS-BREVIS. JOURNAL OF BACTERIOLOGY, 176(12), 3484–3492.

Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Metastases (LM) in the Modern Treatment Era
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Neal, J. W., & Wakelee, H. A. (2012). Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Metastases (LM) in the Modern Treatment Era. JOURNAL OF THORACIC ONCOLOGY, 7(9), S243–S243.

Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer
Bratman, S. V., Eclov, N. C., Modlin, L. A., Neal, J., Loo, B. W., Wu, G., … Diehn, M. (2012). Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S713–S713.

First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
Neal, J. W., & Sequist, L. V. (2010). First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clinical Advances in Hematology & Oncology : H&O, 8(2), 119–126.

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Neal, J. W., Heist, R. S., Fidias, P., Temel, J. S., Huberman, M., Marcoux, J. P., … Sequist, L. V. (2010). Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. Journal of Thoracic Oncology , 5(11), 1855–1858.

A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).
Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., … Wakelee, H. A. (2012). A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 30(15).

The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
Neal, J. W., Pennell, N. A., Govindan, R., Lanuti, M., Rosovsky, R. P. G., Heist, R. S., … Sequist, L. V. (2012). The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 30(15).

The Select Study: A Multicenter Phase II Trial Of Adjuvant Erlotinib In Resected Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer (NSCLC)
Neal, J. W., Pennell, N. A., Govindan, R., Heist, R. S., Shaw, A. T., Muzikansky, A., … Sequist, L. V. (2012). The Select Study: A Multicenter Phase II Trial Of Adjuvant Erlotinib In Resected Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, 7(9), S209–S209.

A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements.
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., Adrouny, A. R., … Wakelee, H. A. (2013). A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. Clinical Lung Cancer, 14(5), 592–95.

Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips.
Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., … Wang, S. X. (2013). Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Lab on a Chip, 14(1), 78–88.

Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Ramchandran, K., … Wakelee, H. A. (2014). Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clinical Lung Cancer, 15(3), 202–6.

Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips
Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., … Wang, S. X. (2014). Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. LAB ON A CHIP, 14(1), 78–88.

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.
Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., … Wakelee, H. A. (2014). A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. British Journal of Cancer, 110(3), 602–8.

Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.
Cagle, P. T., Sholl, L. M., Lindeman, N. I., Alsabeh, R., Divaris, D. X. G., Foulis, P., … Yu, P. P. (2014). Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung. Archives of Pathology & Laboratory Medicine, 138(2), 171–74.

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., … Diehn, M. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine, 20(5), 548–54.

Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.
Riess, J. W., Bhattacharya, N., Blenman, K. R. M., Neal, J. W., Hwang, G., Pultar, P., … Wakelee, H. A. (2014). Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Immunopharmacology and Immunotoxicology, 36(2), 182–86.

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., … Diehn, M. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. NATURE MEDICINE, 20(5), 552–58.

A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab. JOURNAL OF THORACIC ONCOLOGY, 8(2), E17–E18.

Review of the current targeted therapies for non-small-cell lung cancer.
Nguyen, K.-S. H., Neal, J. W., & Wakelee, H. (2014). Review of the current targeted therapies for non-small-cell lung cancer. World Journal of Clinical Oncology, 5(4), 576–87.

Unicentric, multifocal castleman disease of the mediastinum associated with cerebellitis.
Hamaji, M., Neal, J. W., & Burt, B. M. (2015). Unicentric, multifocal castleman disease of the mediastinum associated with cerebellitis. Annals of Thoracic Surgery, 99(1), e7–9.

Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours.
Neal, J. W., & Sledge, G. W. (2014). Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours. Nature Reviews. Clinical Oncology, 11(11), 627–28.

Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.
Liang, Y., Padda, S. K., Riess, J. W., West, R. B., Neal, J. W., & Wakelee, H. A. (2015). Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung Cancer , 87(1), 34–38.

GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.
Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., & Wakelee, H. A. (2015). GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. Anticancer Research, 35(2), 669–76.

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., … Jain, R. K. (2015). Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 112(5), 1547–52.

Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors.
Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., … Wakelee, H. A. (2015). Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors. Journal of Thoracic Oncology , 10(3), 500–508.

Developing biomarker-specific end points in lung cancer clinical trials
Neal, J. W., Gainor, J. F., & Shaw, A. T. (2015). Developing biomarker-specific end points in lung cancer clinical trials. NATURE REVIEWS CLINICAL ONCOLOGY, 12(3), 135–46.

Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond.
Neal, J. W., & Sequist, L. V. (2013). Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. Translational Lung Cancer Research, 2(5), 411–14.

MET inhibitors in combination with other therapies in non-small cell lung cancer.
Padda, S., Neal, J. W., & Wakelee, H. A. (2012). MET inhibitors in combination with other therapies in non-small cell lung cancer. Translational Lung Cancer Research, 1(4), 238–53.

Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., … Camidge, D. R. (2015). Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 372(18), 1700–1709.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Piotrowska, Z., Niederst, M. J., Karlovich, C. A., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M., … Sequist, L. V. (2015). Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery, 5(7), 713–22.

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., & Wakelee, H. A. (2015). Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. LUNG CANCER, 89(3), 280–86.

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer
Liang, Y., Wakelee, H. A., & Neal, J. W. (2015). Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 16(5), 366–73.

Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
Chuang, J. C., Neal, J. W., Niu, X.-M., & Wakelee, H. A. (2015). Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. Lung Cancer , 90(1), 1–7.

Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Leung, L.-S. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., & Marmor, M. F. (2015). Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. American Journal of Ophthalmology, 160(4), 799–805 e1.

Management of Dermatologic Complications of Lung Cancer Therapies.
Pugliese, S. B., Neal, J. W., & Kwong, B. Y. (2015). Management of Dermatologic Complications of Lung Cancer Therapies. Current Treatment Options in Oncology, 16(10), 50-?

Pruritus as a Paraneoplastic Symptom of Thymoma
Padda, S. K., Shrager, J. B., Riess, J. W., Pagtama, J. Y., Tisch, A. J. H., Kwong, B. Y., … Wakelee, H. A. (2015). Pruritus as a Paraneoplastic Symptom of Thymoma. JOURNAL OF THORACIC ONCOLOGY, 10(11), E110–E112.

Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Leung, L.-S. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., & Marmor, M. F. (2015). Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. American Journal of Ophthalmology, 160(4), 799–805 e1.

Management of Dermatologic Complications of Lung Cancer Therapies.
Pugliese, S. B., Neal, J. W., & Kwong, B. Y. (2015). Management of Dermatologic Complications of Lung Cancer Therapies. Current Treatment Options in Oncology, 16(10), 368-?

Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.
Myall, N. J., Neal, J. W., Cho-Phan, C. D., Zhou, L. Y., Stehr, H., Zhou, L., … Wakelee, H. A. (2016). Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. Clinical Lung Cancer, 17(2), e17–21.

Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC
Mak, R. H., Doran, E., Muzikansky, A., Kang, J., Neal, J. W., Baldini, E. H., … Sequist, L. V. (2011). Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC. ONCOLOGIST, 16(6), 886–95.

Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.
Chuang, J. C., & Neal, J. W. (2015). Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. Translational Lung Cancer Research, 4(5), 639–41.

Integrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., … Alizadeh, A. A. (2016). Integrated digital error suppression for improved detection of circulating tumor DNA. NATURE BIOTECHNOLOGY, 34(5), 547–55.

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., … Diehn, M. (2016). Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. NATURE COMMUNICATIONS, 7.

Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.
Chuang, J. C., Shrager, J. B., Wakelee, H. A., & Neal, J. W. (2016). Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. Clinical Therapeutics, 38(7), 1567–76.

Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.
Weiskopf, K., Creighton, D., Lew, T., Caswell, J. L., Ouyang, D., Shah, A. T., … Telli, M. L. (2016). Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction. Journal of Oncology Practice / American Society of Clinical Oncology, 12(8), 763–64.

GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray.
Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., & Wakelee, H. A. (2015). GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray. Anticancer Research, 35(2), 669–76.

Molecular profiling of single circulating tumor cells from lung cancer patients
Park, S.-M., Wong, D. J., Ooi, C. C., Kurtz, D. M., Vermesh, O., Aalipour, A., … Gambhir, S. S. (2016). Molecular profiling of single circulating tumor cells from lung cancer patients. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 113(52), E8379–E8386.

PS01.22: Novel 3-Dimensional Preclinical Models: Topic: Medical Oncology.
Salahudeen, A., De La O, S., Padda, S. K., Neal, J. W., Wakelee, H., & Kuo, C. (2016). PS01.22: Novel 3-Dimensional Preclinical Models: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S282-?

PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology.
Neal, J. W., Wakelee, H., Padda, S. K., Bertrand, S., Acevedo, B., Holmes Tisch, A., … Nagpal, S. (2016). PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S271–S272.

ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Chuang, J. C., Stehr, H., Liang, Y., Das, M., Huang, J., Diehn, M., … Neal, J. W. (2017). ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. Journal of Thoracic Oncology .

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., … Diehn, M. (2016). Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 7, 13513-?

Elusive Target of Angiogenesis in Small-Cell Lung Cancer.
Neal, J. W., & Wakelee, H. A. (2017). Elusive Target of Angiogenesis in Small-Cell Lung Cancer. Journal of Clinical Oncology , JCO2016716084-?

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Huang, Y., … Ramalingam, S. S. (2016). Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. LANCET ONCOLOGY, 17(12), 1661–71.

PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancers and Response to Crizotinib: Topic: Medical Oncology.
Wang, S. X., Zhang, B. M., Wakelee, H., Diehn, M., Kunder, C. A., & Neal, J. W. (2016). PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancers and Response to Crizotinib: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S312–S313.

MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology.
Horn, L., Wakelee, H., Reckamp, K. L., Blumenschein, G., Infante, J. R., Carter, C. A., … Lovly, C. M. (2016). MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S256–S257.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., … Drilon, A. (2017). Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. JOURNAL OF CLINICAL ONCOLOGY, 35(13), 1403-?

Case Series of MET Exon 14 Skipping Mutation-positive Non-Small Cell Lung Cancers and Response to Crizotinib.
Wang, S. X., Zhang, B., Wakelee, H. A., Diehn, M., Kunder, C., & Neal, J. W. (2017). Case Series of MET Exon 14 Skipping Mutation-positive Non-Small Cell Lung Cancers and Response to Crizotinib. International Journal of Radiation Oncology, Biology, Physics, 98(1), 239-?

Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer.
Costa, H. A., Neal, J. W., Bustamante, C. D., & Zehnder, J. L. (2017). Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Molecular Diagnosis & Therapy.

Chart Review Versus an Automated Bioinformatic Approach to Assess Real-World Crizotinib Effectiveness in Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer
Bui, N., Henry, S., Wood, D., Wakelee, H. A., & Neal, J. W. (2017). Chart Review Versus an Automated Bioinformatic Approach to Assess Real-World Crizotinib Effectiveness in Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer. JCO: Clinical Cancer Informatics.

Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
Choi, C. Y., Wakelee, H. A., Neal, J. W., Pinder-Schenck, M. C., Yu, H.-H. M., Chang, S. D., … Soltys, S. G. (2017). Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. International Journal of Radiation Oncology, Biology, Physics, 99(1), 16–21.

Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., … Diehn, M. (2017). Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discovery.

Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A., Stehr, H., Azad, T. D., … Diehn, M. (2017). Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), S114.

Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing
Diehn, M., Bratman, S. V., Newman, A. M., Neal, J. W., Wakelee, H. A., Merritt, R. E., … Alizadeh, A. (2014). Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S75.

Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Merriott, D. J., … Diehn, M. (2017). Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), S1–S2.

Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC
Modlin, L. A., Bratman, S. V., Newman, A. M., Eclov, N. C. W., Neal, J. W., Wakelee, H. A., … Diehn, M. (2014). Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S812.

CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Say, C., … Diehn, M. (2016). CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 96(2), S41–S42.

Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer
Chaudhuri, A., Lovejoy, A., Chabon, J., Newman, A., Stehr, H., Say, C., … Diehn, M. (2017). Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 12(1), S445.

Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer
Merriott, D. J., Chaudhuri, A. A., Jin, M., Chabon, J. J., Newman, A., Stehr, H., … Diehn, M. (2017). Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), S20–S21.

Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing
Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H., … Diehn, M. (2013). Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S92.

Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non-small Cell Lung Cancer
Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C. N., Eclov, N., To, J., Murphy, J. D., … Loo, B. W. (2017). Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non-small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), E456.

Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., … Brahmer, J. R. (2014). Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S36.

Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., … Gensheimer, M. F. (2018). Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. Clinical Lung Cancer.

ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION
Das, M., Padda, S. K., Zhou, L., Frymoyer, A., Neal, J. W., & Wakelee, H. A. (2013). ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION. JOURNAL OF THORACIC ONCOLOGY, 8, S1185–S1186.

Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA)
Padda, S. K., Riess, J., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., … Wakelee, H. A. (2014). Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA). JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.
Vaca, S. D., Connolly, I. D., Ho, C., Neal, J., & Hayden Gephart, M. (2017). Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors. Neurosurgery.

Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?
El-Deiry, W. S., Taylor, B., & Neal, J. W. (2017). Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come? American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting, 37, e8–e15.

Rociletinib-associated cataracts in EGFR-mutant NSCLC
Piotrowska, Z., Liu, E., Varga, A., Thakur, M., Narayanan, V., Liu, S. V., … Sequist, L. V. (2016). Rociletinib-associated cataracts in EGFR-mutant NSCLC. ANNALS OF ONCOLOGY, 27.

ENERGY METABOLISM IN LUNG ADENOCARCINOMA
Hoang, C., Xu, Y., Shi, Z., Lin, Y., Merritt, R. E., Shrager, J., … Wakelee, H. A. (2013). ENERGY METABOLISM IN LUNG ADENOCARCINOMA. JOURNAL OF THORACIC ONCOLOGY, 8, S1036–S1037.

Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer
Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C., Zhu, H., Eclov, N. C. W., To, J., … Loo, B. W. (2017). Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. RADIOTHERAPY AND ONCOLOGY, 125(2), 338–43.

The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer
Chuang, J. C., & Neal, J. W. (2017). The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer. CANCER, 123(15), 2798–2801.

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors
Jahchan, N. S., Dudley, J. T., Mazur, P. K., Flores, N., Yang, D., Palmerton, A., … Sage, J. (2014). A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. CANCER RESEARCH, 74(19).

PEMETREXED IN PATIENTS WITH THYMIC MALIGNANCIES PREVIOUSLY TREATED WITH CHEMOTHERAPY
Liang, Y., Padda, S. K., Riess, J. W., West, R., Neal, J. W., & Wakelee, H. A. (2014). PEMETREXED IN PATIENTS WITH THYMIC MALIGNANCIES PREVIOUSLY TREATED WITH CHEMOTHERAPY. JOURNAL OF THORACIC ONCOLOGY, 9(10), S226.

STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES
Wakelee, H., Riess, J., Pedro-Salcedo, M. S., Padda, S., Ramchandran, K., Gubens, M., & Neal, J. (2013). STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES. JOURNAL OF THORACIC ONCOLOGY, 8, 22–23.

CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts)
Reckamp, K. L., Wakelee, H. A., Patel, S., Blumenschein, G., Neal, J. W., Gitlitz, B., … Horn, L. (2017). CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts). ANNALS OF ONCOLOGY, 28.

PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EXPRESSION IN A THYMOMA TISSUE MICROARRAY (TMA)
Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., … Wakelee, H. A. (2014). PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EXPRESSION IN A THYMOMA TISSUE MICROARRAY (TMA). JOURNAL OF THORACIC ONCOLOGY, 9(10), S212.

Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial
Modlin, L. A., Choi, C. Y. H., Gibbs, I. C., Wakelee, H. A., Neal, J., Pinder-Schenck, M. C., … Soltys, S. G. (2015). Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93(3), S178.

Molecular and Clinicopathologic Features Associated with PD-L1 Expression in Lung Adenocarcinoma
Yang, S., Steiner, D., Berry, G. J., Neal, J. W., Zehnder, J. L., & Kunder, C. A. (2017). Molecular and Clinicopathologic Features Associated with PD-L1 Expression in Lung Adenocarcinoma. JOURNAL OF MOLECULAR DIAGNOSTICS, 19(6), 1009–10.

CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Padda, S. K., Rosenberg-Hasson, Y., Neal, J. W., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., … Zhou, L. (2013). CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC). JOURNAL OF THORACIC ONCOLOGY, 8, S1072–S1073.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., … Kelly, R. J. (2018). Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. LUNG CANCER, 117, 44–49.

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer.
Jahchan, N., Joel, D., Mazur, P., Neal, J., Khatri, P., Butte, A., & Sage, J. (2014). A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer. CLINICAL CANCER RESEARCH, 20.

Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC
Horn, L., Wakelee, H., Reckamp, K., Blumenschein, G., Infante, J., Carter, C., … Lovly, C. (2017). Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC. JOURNAL OF THORACIC ONCOLOGY, 12(1), S1159.

PRURITUS AS A PARANEOPLASTIC SYMPTOM OF THYMOMA
Padda, S. K., Pagtama, J. Y., Tisch, A. H., Neal, J. W., Riess, J. W., Loo, B. W., … Wakelee, H. A. (2014). PRURITUS AS A PARANEOPLASTIC SYMPTOM OF THYMOMA. JOURNAL OF THORACIC ONCOLOGY, 9(10), S240–S241.

A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer
Nagpal, S., Wakelee, H., Padda, S., Bertrand, S., Acevedo, B., Tisch, A. H., … Neal, J. (2017). A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 12(1), S940.

Computed Tomography (CT) Characteristics Associated with the Proposed IASLC/ITMIG TNM Pathologic Staging System for Thymoma
Padda, S. K., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., … Wakelee, H. A. (2015). Computed Tomography (CT) Characteristics Associated with the Proposed IASLC/ITMIG TNM Pathologic Staging System for Thymoma. JOURNAL OF THORACIC ONCOLOGY, 10(9), S196.

GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)
Riess, J. W., West, R., Padda, S. K., Dean, M., Klimowicz, A., Huong, C., … Wakelee, H. A. (2013). GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA). JOURNAL OF THORACIC ONCOLOGY, 8, S944.

Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies
Chuang, J., Neal, J. W., & Wakelee, H. A. (2015). Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies. JOURNAL OF THORACIC ONCOLOGY, 10(9), S549.

VeriStrat (R) and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus /- Erlotinib in Non-Small Cell Lung Cancer
Padda, S. K., Lara, P., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., West, H., … Wakelee, H. A. (2015). VeriStrat (R) and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus /- Erlotinib in Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 10(9), S291.

First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.
Sequist, L. V., Soria, J.-C., Gadgeel, S. M., Wakelee, H. A., Camidge, D. R., Varga, A., … Goldman, J. W. (2013). First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. JOURNAL OF CLINICAL ONCOLOGY, 31(15).

A Phase lb Study of Erlotinib and Momelotinib for EGFR TKI Naive EGFR Mutated Metastatic Non-Small Cell Lung Cancer
Padda, S., Reckamp, K., Koczywas, M., Neal, J., Brachmann, C., Kawashima, J., … Wakelee, H. (2017). A Phase lb Study of Erlotinib and Momelotinib for EGFR TKI Naive EGFR Mutated Metastatic Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES
Wakelee, H. A., Riess, J. W., San Pedro-Salcedo, M., Padda, S. K., Ramchandran, K., Gubens, M. A., & Neal, J. W. (2013). STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES. JOURNAL OF THORACIC ONCOLOGY, 8, S731.

GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)
Riess, J., West, R., Padda, S., Dean, M., Klimowicz, A., Huong, C., … Wakelee, H. (2013). GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA). JOURNAL OF THORACIC ONCOLOGY, 8, 25.

Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC
Heist, R. S., Duda, G. D., Sahani, D., Ancukiewicz, M., Fidias, P., Sequist, L. V., … Jain, R. K. (2011). Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 29(15).

Phase II Trial of Single Agent Amrubicin in Patients with Previously Treated Advanced Thymic Malignancies
Wakelee, H. A., Padda, S. K., Burns, M., Spittler, A. J., Riess, J. W., San Pedro-Salcedo, M., … Loehrer, P. J. (2015). Phase II Trial of Single Agent Amrubicin in Patients with Previously Treated Advanced Thymic Malignancies. JOURNAL OF THORACIC ONCOLOGY, 10(9), S195.

A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC)
Neal, J. W., Wakelee, H. A., Feliciano, J. L., Goldberg, S. B., Morgensztern, D., Das, M. S., … Sequist, L. V. (2014). A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 32(15).

COMPUTED TOMOGRAPHY (CT) CHARACTERISTICS ASSOCIATED WITH MASAOKA-KOGA PATHOLOGIC STAGE IN THYMOMA
Padda, S. K., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., … Wakelee, H. A. (2014). COMPUTED TOMOGRAPHY (CT) CHARACTERISTICS ASSOCIATED WITH MASAOKA-KOGA PATHOLOGIC STAGE IN THYMOMA. JOURNAL OF THORACIC ONCOLOGY, 9(10), S222.

FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)
Soria, J.-C., Sequist, L. V., Gadgeel, S., Goldman, J., Wakelee, H., Varga, A., … Allen, A. (2013). FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M). JOURNAL OF THORACIC ONCOLOGY, 8, S141–S142.

Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC)
Doebele, R., Horn, L., Spira, A., Piotrowska, Z., Costa, D., Neal, J., … Janne, P. (2017). Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, 12(1), S1072–S1073.

Outcomes of Moderately Hypofractionated Intensity-Modulated Thoracic Radiotherapy with Concurrent Chemotherapy for Treatment of Non-Small Cell Lung Cancer
Xiang, M., Gensheimer, M. F., Maxim, P. G., Wakelee, H. A., Neal, J. W., Diehn, M., & Loo, B. W. (2017). Outcomes of Moderately Hypofractionated Intensity-Modulated Thoracic Radiotherapy with Concurrent Chemotherapy for Treatment of Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), E504.

VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS
Nguyen, K.-S. H., Das, M., Ramchandran, K., Shrager, J., Merritt, R. E., Hoang, C., … Neal, J. W. (2013). VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS. JOURNAL OF THORACIC ONCOLOGY, 8, S208–S209.

Novel systemic therapy against malignant pleural mesothelioma
Mancuso, M. R., & Neal, J. W. (2017). Novel systemic therapy against malignant pleural mesothelioma. TRANSLATIONAL LUNG CANCER RESEARCH, 6(3), 295–314.

Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing.
Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H. A., … Alizadeh, A. A. (2014). Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma
Wakelee, H., Melnikova, V., Karlovich, C., Gadgeel, S., Reckamp, K., Goldman, J. W., … Sequist, L. (2017). A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma. JOURNAL OF THORACIC ONCOLOGY, 12(1), S384–S385.

Improved survival among lung cancer patients taking antidepressants
Zingone, A., Brown, D., Bowman, E., Vidal, O., Neal, J., Sage, J., & Ryan, B. M. (2015). Improved survival among lung cancer patients taking antidepressants. CANCER RESEARCH, 75.

Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., … Diehn, M. (2017). Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 98(2), E4.

PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER
Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., … Blayney, D. (2013). PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER. JOURNAL OF THORACIC ONCOLOGY, 8, S1324.

Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors
Padda, S. K., Terrone, D., Tian, L., Khuong, A., Neal, J. W., Riess, J. W., … Wakelee, H. A. (2018). Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors. JOURNAL OF THORACIC IMAGING, 33(3), 176–83.

SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.
Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., … Sequist, L. V. (2014). SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512).
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D. P., & Ramalingam, S. S. (2015). Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512). JOURNAL OF CLINICAL ONCOLOGY, 33(15).

A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D. P., & Ramalingam, S. S. (2015). A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512. JOURNAL OF THORACIC ONCOLOGY, 10(9), S373.

Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).
Wakelee, H. A., Padda, S. K., Burns, M., Spittler, A. J., Riess, J., San Pedro-Salcedo, M., … Loehrer, P. J. (2015). Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM). JOURNAL OF CLINICAL ONCOLOGY, 33(15).

Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma
Gao, R. W., Berry, M. F., Kunder, C. A., Khuong, A. A., Wakelee, H., Neal, J. W., … Shrager, J. B. (2017). Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 154(6), 2092-+.

Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)
Horn, L., Wakelee, H., Blumenschein, G., Reckamp, K., Waqar, S., Carter, C. A., … Lovly, C. (2016). Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx). ANNALS OF ONCOLOGY, 27.

Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
Chaudhuri, A. A., Nabet, B. Y., Merriott, D. J., Jin, M., Chen, E. L., Chabon, J. J., … Diehn, M. (2018). Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.

Antimicrobial resistance due to antibiotic use for EGFR inhibitor related papulopustular skin reaction
Hirotsu, K., Subramanian, A., Neal, J., Li, S., Pugliese, S., & Kwong, B. (2018). Antimicrobial resistance due to antibiotic use for EGFR inhibitor related papulopustular skin reaction. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 138(5), S176.

Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer.
Zweig, J. R., & Neal, J. W. (2018). Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018788554.

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Horn, L., Infante, J. R., Reckamp, K. L., Blumenschein, G. R., Leal, T. A., Waqar, S. N., … Wakelee, H. A. (2018). Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. CLINICAL CANCER RESEARCH, 24(12), 2771–79.

Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations.
Wang, S. X., Lei, L., Guo, H. H., Shrager, J., Kunder, C. A., & Neal, J. W. (2018). Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations. Lung Cancer (Amsterdam, Netherlands), 122, 187–91.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Brahmer, J. R., Govindan, R., Anders, R. A., Antonia, S. J., Sagorsky, S., Davies, M. J., … Herbst, R. S. (2018). The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). JOURNAL FOR IMMUNOTHERAPY OF CANCER, 6, 75.

Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., & Neal, J. W. (2018). Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. The Oncologist.

Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer.
Sun, T. Y., Niu, X., Chakraborty, A., Neal, J. W., & Wakelee, H. A. (2018). Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data
Leal, T., Wakelee, H., Reckamp, K., Waqar, S., Patel, S., Blumenschein, G., … Horn, L. (2018). Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data. JOURNAL OF THORACIC ONCOLOGY, 13(9), S156.

Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam.
Nguyen, K.-S. H., Stehr, H., Zhou, L., Nguyen, A.-H., Hiep, P. N., Van Cau, N., … Neal, J. W. (2018). Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. Journal of Global Oncology, (4), 1–9.

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., … Sequist, L. V. (2018). SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1800131.

Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.
Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., & Wakelee, H. A. (2018). Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. Clinical Lung Cancer.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux, N., Gettinger, S. N., O'Kane, G., Arbour, K. C., Neal, J. W., Husain, H., … Sequist, L. V. (2018). EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801585.

Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center
Myall, N., Henry, S., Wood, D., Neal, J., & Wakelee, H. (2018). Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center. JOURNAL OF THORACIC ONCOLOGY, 13(10), S489–S490.

Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC
Neal, J., Doebele, R., Riely, G., Spira, A., Horn, L., Piotrowska, Z., … Janne, P. (2018). Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC. JOURNAL OF THORACIC ONCOLOGY, 13(10), S599.

Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Wang, S. X., Zhang, B. M., Wakelee, H. A., Koontz, M. Z., Pan, M. G., Diehn, M., … Neal, J. W. (2019). Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. Anti-Cancer Drugs.

Increased Galectin-1 Expression in Thymic Epithelial Tumors.
Riess, J. W., Kong, C. S., West, R. B., Padda, S. K., Neal, J. W., Wakelee, H. A., & Le, Q.-T. (2018). Increased Galectin-1 Expression in Thymic Epithelial Tumors. Clinical Lung Cancer.

Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials
Lam, V. K., Hong, D. S., Heymach, J. V., Blumenschein, G., Butler, M. O., Johnson, M., … Amado, R. G. (2018). Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. ANNALS OF ONCOLOGY, 29.

Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms
Davidzon, G., Wakelee, H., Neal, J., Mittra, E., Quon, A., & Iagaru, A. (2012). Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms. JOURNAL OF NUCLEAR MEDICINE, 53.

Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?
El-Deiry, W. S., Taylor, B., & Neal, J. W. (2017). Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come? American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, (37), e8–e15.

Relationship between anti-depressant use and lung cancer survival.
Zingone, A., Brown, D., Bowman, E. D., Vidal, O., Sage, J., Neal, J., & Ryan, B. M. (2017). Relationship between anti-depressant use and lung cancer survival. Cancer Treatment and Research Communications, 10, 33–39.

Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts)
Wolf, J., Baik, C., Heist, R. S., Neal, J. W., Mansfield, A. S., Buettner, R., … Awad, M. M. (2018). Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts). EUROPEAN JOURNAL OF CANCER, 103, E131.

Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis
Sun, T. Y., Sung, A. W., & Neal, J. W. (2019). Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis. JOURNAL OF THORACIC ONCOLOGY, 14(4), E75–E77.

Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis.
Sun, T. Y., Sung, A. W., & Neal, J. W. (2019). Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 14(4), e75–e77.

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., & Wakelee, H. A. (2015). Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. Lung Cancer (Amsterdam, Netherlands), 89(3), 280–6.

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
Liang, Y., Wakelee, H. A., & Neal, J. W. (2015). Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer. Clinical Lung Cancer, 16(5), 366–73.

Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption.
Hirotsu, K., Dang, T. M., Li, S., Neal, J. W., Pugliese, S., Subramanian, A., & Kwong, B. Y. (2019). Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption. JAMA Dermatology.

Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA
Chabon, J., Chaudhuri, A., Azad, T., Kurtz, D., Stehr, H., Liu, C. L., … Diehn, M. (2017). Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA. JOURNAL OF THORACIC ONCOLOGY, 12(11), S1851.

A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naive EGFR-Mutated Metastatic Non-Small Cell Lung
Padda, S., Reckamp, K., Koczywas, M., Neal, J., Kawashima, J., Kong, S., … Wakelee, H. (2017). A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naive EGFR-Mutated Metastatic Non-Small Cell Lung. JOURNAL OF THORACIC ONCOLOGY, 12(11), S2142–S2143.

EGFR Genotyping of Matched Urine, Plasma , and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor
Goldman, J. W., Karlovich, C., Sequist, L., Melnikova, V., Franovic, A., Gadgeel, S. M., … Wakelee, H. A. (2018). EGFR Genotyping of Matched Urine, Plasma , and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO PRECISION ONCOLOGY, 2, 1–13.

Response to Ensartinib in TKI Naive ALK plus NSCLC Patients
Wakelee, H., Sanborn, R., Nieva, J., Waqar, S., Brzezniak, C., Bauman, J., … Horn, L. (2017). Response to Ensartinib in TKI Naive ALK plus NSCLC Patients. JOURNAL OF THORACIC ONCOLOGY, 12(11), S1826.

Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer
Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., & Wakelee, H. A. (2019). Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. CLINICAL LUNG CANCER, 20(2), E208–E217.

Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations
Wang, S. X. Y., Lei, L., Guo, H. H., Shrager, J., Kunder, C. A., & Neal, J. W. (2018). Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations. LUNG CANCER, 122, 187–91.

Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib
Wang, S. X. Y., Zhang, B. M., Wakelee, H. A., Koontz, M. Z., Pan, M. G., Diehn, M., … Neal, J. W. (2019). Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. ANTI-CANCER DRUGS, 30(5), 537–41.

Increased Galectin-1 Expression in Thymic Epithelial Tumors
Riess, J. W., Kong, C. S., West, R. B., Padda, S. K., Neal, J. W., Wakelee, H. A., & Le, Q.-T. (2019). Increased Galectin-1 Expression in Thymic Epithelial Tumors. CLINICAL LUNG CANCER, 20(3), E356–E361.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., … Gautschi, O. (2019). Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of Oncology : Official Journal of the European Society for Medical Oncology.

Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., … Gensheimer, M. F. (2018). Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. CLINICAL LUNG CANCER, 19(5), E581–E588.

Organoid-based characterization of patient tumors and microenvironments at single cell resolution
Salahudeen, A. A., Zhu, J., Ju, J., Batish, A., Sutha, K., Neal, J. T., … Kuo, C. J. (2018). Organoid-based characterization of patient tumors and microenvironments at single cell resolution. CANCER RESEARCH, 78(13).

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019). Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. Lung Cancer (Amsterdam, Netherlands), 133, 144–50.

Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam
Nguyen, K.-S. H., Stehr, H., Zhou, L., Anh-Hoa Nguyen, Pham Nhu Hiep, Nguyen Van Cau, … Neal, J. W. (2018). Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. JOURNAL OF GLOBAL ONCOLOGY, 4.

Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer
Sun, T. Y., Niu, X., Chakraborty, A., Neal, J. W., & Wakelee, H. A. (2019). Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 14(2), E21–E24.

Review of the current targeted therapies for non-small-cell lung cancer
Nguyen, K.-S. H., Neal, J. W., & Wakelee, H. (2014). Review of the current targeted therapies for non-small-cell lung cancer. WORLD JOURNAL OF CLINICAL ONCOLOGY, 5(4), 576–87.

MET inhibitors in combination with other therapies in non-small cell lung cancer
Padda, S., Neal, J. W., & Wakelee, H. A. (2012). MET inhibitors in combination with other therapies in non-small cell lung cancer. TRANSLATIONAL LUNG CANCER RESEARCH, 1(4), 238–53.

Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., & Neal, J. W. (2019). Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. ONCOLOGIST, 24(6), 836–43.

Plasma genotyping of patients enrolled on the expansion phase VII trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC).
Horn, L., Wakelee, H. A., Reckamp, K. L., Blumenschein, G. R., Infante, J. R., Carter, C. A., … Lovly, C. M. (2016). Plasma genotyping of patients enrolled on the expansion phase VII trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.
Chabon, J. ., Simmons, A., Newman, A. M., Lovejoy, A. F., Esfahani, M. S., Haringsma, H., … Diehn, M. (2016). Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer
Zweig, J. R., & Neal, J. W. (2018). Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY, 36(26), 2677-+.

Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors
Vaca, S. D., Connolly, I. D., Ho, C., Neal, J., & Gephart, M. H. (2018). Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors. NEUROSURGERY, 82(1), E6–E14.

Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond
Neal, J. W., & Sequist, L. V. (2013). Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. TRANSLATIONAL LUNG CANCER RESEARCH, 2(5), 411–14.

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Nguyen, K.-S. H., & Neal, J. W. (2012). First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. BIOLOGICS-TARGETS & THERAPY, 6, 337–45.

Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
Hellyer, J. A., Stehr, H., Das, M., Padda, S. K., Ramchandran, K., Neal, J. W., … Wakelee, H. A. (2019). Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 134, 42–45.

Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.
Wakelee, H. A., Gadgeel, S. M., Goldman, J. W., Reckamp, K. L., Karlovich, C. A., Melnikova, V., … Sequist, L. V. (2016). Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., … Diehn, M. (2016). Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019). Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes". Lung Cancer (Amsterdam, Netherlands).

Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption
Hirotsu, K., Dang, T. M., Li, S., Neal, J. W., Pugliese, S., Subramanian, A., & Kwong, B. Y. (2019). Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption. JAMA DERMATOLOGY, 155(7), 848–50.

Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.
Jeong, Y., Hellyer, J. A., Stehr, H., Hoang, N. T., Niu, X., Das, M., … Diehn, M. (2019). Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.
Hellyer, J. A., Gubens, M. A., Cunanan, K. M., Padda, S. K., Burns, M., Spittler, A. J., … Loehrer, P. J. (2019). Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer (Amsterdam, Netherlands), 137, 71–75.

ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.
Moding, E. J., Liu, Y., Nabet, B., Chabon, J. J., Chaudhuri, A., Hui, A. B., … Diehn, M. (2019). ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(15).

Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.
Neal, J. W., Hausrath, D., Wakelee, H. A., Cunanan, K., Liu, S. V., Banwait, M., … Piotrowska, Z. (2019). Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis. JOURNAL OF CLINICAL ONCOLOGY, 37(15).

Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.
Chaft, J. E., Costa, D. B., Muzikansky, A., Shrager, J. B., Lanuti, M., Huang, J., … Neal, J. W. (2019). Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 37(15).

Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.
Janne, P. A., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Horn, L., … Riely, G. J. (2019). Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. JOURNAL OF CLINICAL ONCOLOGY, 37(15).

Characterization of circulating tumor cells and its PD-L1 expression with high-sensitivity liquid biopsy panel in non-small cell lung cancer patients
Liu, X., Ao, Z., Preiss, J. S., Neal, J., Zhou, L. Y., Sambucetti, L., & Wakelee, H. A. (2019). Characterization of circulating tumor cells and its PD-L1 expression with high-sensitivity liquid biopsy panel in non-small cell lung cancer patients. CANCER RESEARCH, 79(13).

A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer
Reckamp, K. L., Akerley, W., Edelman, M. J., Halmos, B., He, K., Johnson, M., … Lam, V. (2019). A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer. CANCER RESEARCH, 79(13).

Clinical and molecular characteristics of responders versus non-responders to immune checkpoint inhibitors (ICI) in NSCLC.
Shah, A., Padda, S. K., & Neal, J. W. (2019). Clinical and molecular characteristics of responders versus non-responders to immune checkpoint inhibitors (ICI) in NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 37(8).

Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions
Jaenne, P., Neal, J. W., Camidge, D. R., Spira, A., Piotrowska, Z., Horn, L., … Riely, G. J. (2019). Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions. ANNALS OF ONCOLOGY, 30.

Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer Patients Treated with Ensartinib
Wakelee, H., Reckamp, K., Leal, T., Chiappori, A., Waqar, S., Zeman, K., … Horn, L. (2019). Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer Patients Treated with Ensartinib. JOURNAL OF THORACIC ONCOLOGY, 14(10), S566.

STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
Skoulidis, F., Arbour, K., Hellmann, M., Patil, P., Marmarelis, M., Owen, D., … Heymach, J. (2019). STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. JOURNAL OF THORACIC ONCOLOGY, 14(10), S294–S295.

A Single-Cell Resolution Map of EMT and Drug Resistance States for Evaluating NSCLC Clinical Specimens
Karacosta, L., Anchang, B., Ignatiadis, N., Kimmey, S., Benson, J., Shrager, J., … Plevritis, S. (2019). A Single-Cell Resolution Map of EMT and Drug Resistance States for Evaluating NSCLC Clinical Specimens. JOURNAL OF THORACIC ONCOLOGY, 14(10), S226–S227.

The Real-World Risk of Brain Metastases in Stage 3 Lung Cancer Patients in the Era of PET and MRI Staging
Ko, R., Therkelsen, K., Von Eyben, R., Neal, J., Loo, B., & Nagpal, S. (2019). The Real-World Risk of Brain Metastases in Stage 3 Lung Cancer Patients in the Era of PET and MRI Staging. JOURNAL OF THORACIC ONCOLOGY, 14(10), S585–S586.

Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions
Riely, G., Neal, J., Camidge, D. R., Spira, A., Piotrowska, Z., Horn, L., … Janne, P. (2019). Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions. JOURNAL OF THORACIC ONCOLOGY, 14(10), S412–S413.

Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study
Reckamp, K. L., Akerley, W., Calvo, E., Clarke, J., Edelman, M. J., He, K., … Johnson, M. L. (2019). Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study. ANNALS OF ONCOLOGY, 30, 657-+.

Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)
Leal, T., Wakelee, H., Reckamp, K. L., Chiappori, A., Oxnard, G. R., Waqar, S. N., … Horn, L. (2019). Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2). JOURNAL OF THORACIC ONCOLOGY, 14(11), S1171–S1172.

Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC.
Hellmann, M. D., Nabet, B. Y., Rizvi, H., Chaudhuri, A. A., Wells, D. K., Dunphy, M. P., … Diehn, M. (2020). Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials.
Lam, V. K., Hong, D. S., Heymach, J. V., Blumenschein, G., Butler, M. O., Johnson, M., … Amado, R. G. (2018). Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29 Suppl 8, viii731.

Integrating genomic features for non-invasive early lung cancer detection
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., … Diehn, M. (2020). Integrating genomic features for non-invasive early lung cancer detection. NATURE.

Feasibility and design of a cloud-based digital platform in patients with advanced cancer.
Roy, M., Hall, E. T., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., … Ramchandran, K. (2019). Feasibility and design of a cloud-based digital platform in patients with advanced cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(27).

Integrating genomic features for non-invasive early lung cancer detection.
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., … Diehn, M. (2020). Integrating genomic features for non-invasive early lung cancer detection. Nature, 580(7802), 245–251.

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).
Mazieres, J., Drilon, A. E., Mhanna, L., Milia, J., Lusque, A., Cortot, A. B., … Gautschi, O. (2018). Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget). JOURNAL OF CLINICAL ONCOLOGY, 36(15).

Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2020). Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. NATURE CANCER, 1.

A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS.
Riess, J. W., Jahchan, N. S., Das, M., Zach Koontz, M., Kunz, P. L., Wakelee, H. A., … Neal, J. W. (2020). A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. Cancer Treatment and Research Communications, 23, 100174.

Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).
Marcoux, N., Gettinger, S. N., O'Kane, G. M., Arbour, K. C., Neal, J. W., Husain, H., … Sequist, L. V. (2018). Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC). JOURNAL OF CLINICAL ONCOLOGY, 36(15).

Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments.
Salahudeen, A. A., Zhu, J., Ju, J., Giangarra, V., Montesclaros, L., Sapida, J., … Kuo, C. J. (2018). Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments. JOURNAL OF CLINICAL ONCOLOGY, 36(15).

PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.
Zhou, M., Joshi, N., Raj, K. P., Wakelee, H., & Neal, J. W. (2020). PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review. Clinical Lung Cancer.

First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC).
Doebele, R. C., Riely, G. J., Spira, A. I., Horn, L., Piotrowska, Z., Costa, D. B., … Janne, P. A. (2018). First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 36(15).

Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
Waliany, S., Lee, D., Witteles, R. M., Neal, J. W., Nguyen, P., Davis, M. M., … Zhu, H. (2020). Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. Annual Review of Pharmacology and Toxicology.

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H., … Diehn, M. (2020). Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell.

KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., … Diehn, M. (2020). KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 38(15).

Discovery of a novel shared tumor antigen in human lung cancer.
Tseng, D., Chiou, S.-H., Yang, X., Reuben, A., Wilhelmy, J., McSween, A., … Davis, M. (2020). Discovery of a novel shared tumor antigen in human lung cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.
Moding, E. J., Esfahani, M. S., Nabet, B., Liu, Y., Chabon, J. J., He, J., … Diehn, M. (2020). A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Distress screening through PROMIS at an academic cancer center and network site: Implementation of a hybrid model.
Roy, M., Neal, J. W., Bugos, K., Sharp, C., Falconer, P., Rosenthal, E. L., … Ramchandran, K. (2020). Distress screening through PROMIS at an academic cancer center and network site: Implementation of a hybrid model. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.
Ji, J., Aredo, J., Piper-Vallillo, A., Huppert, L., Rotow, J. K., Husain, H., … Riess, J. W. (2020). Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study. JOURNAL OF CLINICAL ONCOLOGY, 38(15).

High-dose osimertinib for CNS progression in EGFR plus non-small cell lung cancer (NSCLC): A multi-institutional experience.
Piper-Vallillo, A., Rotow, J. K., Aredo, J., Shaverdashvili, K., Luo, J., Carlisle, J. W., … Piotrowska, Z. (2020). High-dose osimertinib for CNS progression in EGFR plus non-small cell lung cancer (NSCLC): A multi-institutional experience. JOURNAL OF CLINICAL ONCOLOGY, 38(15).

Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.
Horn, L., Lin, H. M., Padda, S. K., Aggarwal, C., McCoach, C. E., Zhu, Y., … Neal, J. W. (2020). Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. JOURNAL OF CLINICAL ONCOLOGY, 38(15).

Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.
Neal, J. W., Lim, F. L., Felip, E., Gentzler, R. D., Patel, S. B., Baranda, J., … Ponce Aix, S. (2020). Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study. JOURNAL OF CLINICAL ONCOLOGY, 38(15).

KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.
Binkley, M. S., Jeon, Y.-J. J., Nesselbush, M., Moding, E. J., Nabet, B. Y., Almanza, D., … Diehn, M. (2020). KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition. Cancer Discovery.

Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins)
Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A., Piotrowska, Z., Horn, L., … Janne, P. A. (2020). Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins). ANNALS OF ONCOLOGY, 31, S815–S816.

Comparison of clinical outcomes of patients with METDex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients
Wolf, J., Neal, J. W., Mansfield, A. S., Doban, V., Kanakamedala, H., Wu, W.-H., … Baik, C. S. (2020). Comparison of clinical outcomes of patients with METDex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients. ANNALS OF ONCOLOGY, 31, S863.

Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC)
Mazieres, J., Tomasini, P., Lusque, A., Boucekine, M., Gautschi, O., Cortot, A. B., … Barlesi, F. (2020). Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). ANNALS OF ONCOLOGY, 31, S826–S827.

Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer
Shukla, N. D., Salahudeen, A. A., Padda, S. K., Neal, J. W., Wakelee, H. A., & Kuo, C. J. (2018). Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer. CLINICAL CANCER RESEARCH, 24(17).

Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer.
Park, M., Ho, D. Y., Wakelee, H. A., & Neal, J. W. (2020). Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer. Clinical Lung Cancer.

Relative Impact of Anticancer Therapy on Unplanned Hospital Care in Patients With Non-Small-Cell Lung Cancer.
Shah, M. P., & Neal, J. W. (2020). Relative Impact of Anticancer Therapy on Unplanned Hospital Care in Patients With Non-Small-Cell Lung Cancer. JCO Oncology Practice, OP2000612.

Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.
Nesvet, J. C., Antilla, K. A., Pancirer, D. S., Lozano, A. X., Preiss, J. S., Ma, W., … Wang, S. X. (2021). Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. Clinical Chemistry.

Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang, M., Rodrigues, A. J., Pollom, E. L., Gibbs, I. C., Soltys, S. G., Hancock, S. L., … Li, G. (2021). Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. Journal of Neuro-Oncology.

Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis
Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., … Wu, S. M. (2020). Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis. CIRCULATION RESEARCH. LIPPINCOTT WILLIAMS & WILKINS.

Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC.
Hellyer, J. A., Aredo, J. V., Das, M., Ramchandran, K., Padda, S. K., Neal, J. W., & Wakelee, H. A. (2021). Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
Aredo, J. V., Hellyer, J. A., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., … Wakelee, H. A. (2021). Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy. JOURNAL OF THORACIC ONCOLOGY, 16(1), S15.

Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.
Aredo, J. V., Mambetsariev, I., Hellyer, J. A., Amini, A., Neal, J. W., Padda, S. K., … Wakelee, H. A. (2021). Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
White, M. N., Piotrowska, Z., Stirling, K., Liu, S. V., Banwait, M. K., Cunanan, K., … Neal, J. W. (2021). Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clinical Lung Cancer.

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial.
Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Costa, D. B., … Janne, P. A. (2021). Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. Cancer Discovery.

A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer
Nabet, B. Y., Esfahani, M. S., Hamilton, E. G., Chabon, J. J., Moding, E. J., Rizvi, H., … Diehn, M. (2020). A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).
Skoulidis, F., Neal, J. W., Akerley, W. L., Paik, P. K., Papagiannakopoulos, T., Reckamp, K. L., … Rizvi, N. A. (2020). A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC). JOURNAL OF CLINICAL ONCOLOGY, 38(15).

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery.
Chiou, S.-H. H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., … Davis, M. M. (2021). Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity, 54(3), 586–602.e8.

Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.
Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., … Zhu, H. (2021). Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC. CardioOncology, 3(1), 137–39.

Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model.
Neal, J. W., Roy, M., Bugos, K., Sharp, C., Galatin, P. S., Falconer, P., … Ramchandran, K. (2021). Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model. JCO Oncology Practice, OP2000473.

Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib
White, M., Neal, J. W., Gardner, R. M., Cunanan, K. M., Das, M., Padda, S. K., … Wakelee, H. (2021). Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib. JOURNAL OF THORACIC ONCOLOGY, 16(4), S773–S774.

LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis
Mack, P., Minichielle, K., Redman, M., Tolba, K., Kozono, D., Waqar, S., … Herbst, R. (2021). LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers
Roy, M., Fardeen, T., Generalova, O., Hall, E., Cunanan, K., Das, M., … Ramchandran, K. (2021). Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A
Hirsch, F., Hua, X., Wu, M., Neal, J., Cheng, H., Gettinger, S., … Kozono, D. (2021). Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma
Aredo, J., Wakelee, H. A., Neal, J., & Padda, S. (2021). Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors
Padda, S., Whisenant, J., Neal, J., York, S., Iams, W., Neuss, M., … Horn, L. (2021). Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis: Secondary Analysis of NLST
Su, C. C., Wu, J., Neal, J., Popat, R., Backhus, L., Leung, A., … Han, S. (2021). Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis: Secondary Analysis of NLST. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era
Remon, J., Lacas, B., Herbst, R., Reck, M., Garon, E., Scagliotti, G., … Besse, B. (2021). ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021
Neal, J., Lim, F., Felip, E., Gentzler, R., Patel, S., Baranda, J., … Ponce Aix, S. (2021). Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer
Padda, S. K., Aredo, J., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., … Wakelee, H. A. (2021). Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer. JCO PRECISION ONCOLOGY, 5, 153–62.

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer
Neal, J. W., Costa, D. B., Muzikansky, A., Shrager, J. B., Lanuti, M., Huang, J., … Chaft, J. E. (2021). Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer. JCO PRECISION ONCOLOGY, 5, 325–32.

Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., … Diehn, M. (2021). Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer.
Moding, E. J., Liu, Y., Hui, A. B., He, J., Qiao, Y., Xu, T., … Diehn, M. (2021). Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
Su, C. C., Wu, J. T., Neal, J. W., Popat, R. A., Kurian, A. W., Backhus, L. M., … Han, S. S. (2021). Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
Shah, M. P., Aredo, J. V., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Das, M. S., & Neal, J. W. (2021). EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. Clinical Lung Cancer.

The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer
Ellis-Caleo, T., & Neal, J. W. (2021). The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer. JOURNAL OF THORACIC DISEASE.

Radiological tumour classification across imaging modality and histology
Wu, J., Li, C., Gensheimer, M., Padda, S., Kato, F., Shirato, H., … Li, R. (2021). Radiological tumour classification across imaging modality and histology. NATURE MACHINE INTELLIGENCE.

Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.
Waliany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., … Neal, J. W. (2021). Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2020). Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nature Cancer, 1(2), 176–183.

Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., … Ramchandran, K. (2021). Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer. Journal of Patient-Reported Outcomes, 5(1), 91.

Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management
Filsoof, D., Padda, S. K., Garcia, P., Stedman, M., Neal, J. W., Wakelee, H. A., … Katsumoto, T. R. (2021). Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. AMER THORACIC SOC.

Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study
Filsoof, D., Im, J., Garcia, P., Stedman, M., Anand, S., Neal, J. W., … Raj, R. (2021). Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. AMER THORACIC SOC.

The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer.
Ellis-Caleo, T., & Neal, J. W. (2021). The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer. Journal of Thoracic Disease, 13(8), 4864–4871.

Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion
Ou, S.-H. I., Lin, H. M., Hong, J.-L., Yin, Y., Jin, S., Lin, J., … Neal, J. W. (2021). Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion. ANNALS OF ONCOLOGY. ELSEVIER.

Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., … Vitzthum, L. (2021). Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 111(3S), e435.

A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR).
Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., … Diehn, M. (2021). A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR). International Journal of Radiation Oncology, Biology, Physics, 111(3S), S89–S90.

Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., … Ramchandran, K. (2021). Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

A Predictive Model to Guide Brain MRI Surveillance in Patients With Metastatic Lung Cancer: Impact on Real World Outcomes
Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., … Han, S. (2021). A Predictive Model to Guide Brain MRI Surveillance in Patients With Metastatic Lung Cancer: Impact on Real World Outcomes. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Survival After Distant Recurrent Versus De Novo Stage IV Metastatic Lung Cancer Under Low-Dose Computed Tomography Screening
Su, C., Choi, E., Wu, J., Neal, J., Kurian, A., Backhus, L., … Han, S. (2021). Survival After Distant Recurrent Versus De Novo Stage IV Metastatic Lung Cancer Under Low-Dose Computed Tomography Screening. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
Padda, S. K., Reckamp, K. L., Koczywas, M., Neal, J. W., Kawashima, J., Kong, S., … Wakelee, H. A. (2021). A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology.

Mobocertinib in EGFR Exon 20 InsertionePositive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
Spira, A., Ramalingam, S., Neal, J., Piotrowska, Z., Mekhail, T., Tsao, A., … Janne, P. (2021). Mobocertinib in EGFR Exon 20 InsertionePositive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.
Aredo, J. V., Hellyer, J. A., Neal, J. W., & Wakelee, H. A. (2021). Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 16(12), 1994–1998.

Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents
Lau, B., No, H. J., Wu, Y. F., Ko, R. B., Devine, M., Das, M., … Vitzthum, L. (2021). Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.

Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer
Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., … Vitzthum, L. (2021). Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.

A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR)
Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., … Diehn, M. (2021). A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.

Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.
Ou, S.-H. I., Lin, H. M., Hong, J.-L., Yin, Y., Jin, S., Lin, J., … Neal, J. W. (2021). Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy.
Neal, J. W., Kundu, P., Tanaka, T., Enquist, I., Patel, S., Balestrini, A., … Kim, S.-W. (2021). CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.
Hellyer, J. A., White, M. N., Gardner, R. M., Cunanan, K., Padda, S. K., Das, M., … Wakelee, H. A. (2021). Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clinical Lung Cancer.

Radiological tumor classification across imaging modality and histology.
Wu, J., Li, C., Gensheimer, M., Padda, S., Kato, F., Shirato, H., … Li, R. (2021). Radiological tumor classification across imaging modality and histology. Nature Machine Intelligence, 3, 787–798.

Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
White, M. N., Piper-Vallillo, A. J., Gardner, R. M., Cunanan, K., Neal, J. W., Das, M., … Wakelee, H. A. (2021). Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clinical Lung Cancer.

The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer.
Choi, E., Luo, S. J., Aredo, J. V., Backhus, L. M., Wilkens, L. R., Su, C. C., … Han, S. S. (2021). The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer. Journal of the National Cancer Institute.

Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.
Aredo, J. V., Wakelee, H. A., Neal, J. W., & Padda, S. K. (1800). Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications, 30, 100497.

Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer.
Padda, S. K., Aredo, J. V., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., … Wakelee, H. A. (2021). Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer. JCO Precision Oncology, 5, 153–162.

EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
Goldman, J. W., Karlovich, C., Sequist, L. V., Melnikova, V., Franovic, A., Gadgeel, S. M., … Wakelee, H. A. (2018). EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2, 1–13.

Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
Chao, Y., Zhou, J., Hsu, S., Ding, N., Li, J., Zhang, Y., … Hu, J. (2022). Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. TRANSLATIONAL LUNG CANCER RESEARCH.

ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.
Remon, J., Lacas, B., Herbst, R., Reck, M., Garon, E. B., Scagliotti, G. V., … Besse, B. (2022). ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal of Cancer (Oxford, England : 1990), 166, 112–125.

Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.
Chao, Y., Zhou, J., Hsu, S., Ding, N., Li, J., Zhang, Y., … Hu, J. (2022). Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. Translational Lung Cancer Research, 11(2), 295–306.

Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
Shah, M. P., & Neal, J. W. (2022). Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. Drugs.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.
Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M., Dubinett, S. M., Ferris, A., … Herbst, R. S. (2022). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. Journal for Immunotherapy of Cancer, 10(5).

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.
Piper-Vallillo, A. J., Rotow, J. K., Aredo, J. V., Shaverdashvili, K., Luo, J., Carlisle, J. W., … Piotrowska, Z. (2022). High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clinical and Research Reports, 3(6), 100328.

Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.
No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., … Vitzthum, L. K. (2022). Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms. International Journal of Radiation Oncology, Biology, Physics.

Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Vivian Huang, Y., Ryan, J., … Wu, S. M. (2022). Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis. Circulation, 101161CIRCULATIONAHA121056730.

Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.
Waliany, S., Wakelee, H., Ramchandran, K., Das, M., Huang, J., Myall, N., … Neal, J. W. (2022). Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens. Clinical Lung Cancer.

Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data.
Liu, R., Rizzo, S., Waliany, S., Garmhausen, M. R., Pal, N., Huang, Z., … Zou, J. (2022). Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data. Nature Medicine.

Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study.
Lu, D., Ma, Z., Huang, D., Zhang, J., Li, J., Zhi, P., … Wang, J. (2022). Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study. Translational Lung Cancer Research, 11(6), 1119–1131.

Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
Devine, M., Merriott, D. J., No, H. J., Lau, B., Say, C., Yoo, C., … Vitzthum, L. K. (2022). Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. Practical Radiation Oncology.

Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.
Chu, T., Zhang, W., Zhang, B., Zhong, R., Zhang, X., Gu, A., … Han, B. (2022). Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study. Translational Lung Cancer Research, 11(7), 1394–1404.